Celularity Granted European Patent EP3957315 For Treatment Of Diabetic Peripheral Neuropathy Using Placental Cells
Portfolio Pulse from Benzinga Newsdesk
Celularity has been granted European Patent EP3957315 for the treatment of diabetic peripheral neuropathy using placental cells. This patent could potentially open new markets and revenue streams for the company.

May 15, 2024 | 6:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Celularity has been granted European Patent EP3957315 for the treatment of diabetic peripheral neuropathy using placental cells. This patent could potentially open new markets and revenue streams for the company.
The granting of a European patent for a new treatment method can significantly enhance Celularity's market position and revenue potential. This development is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100